
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**

FOR THE MONTH OF APRIL 2021

COMMISSION FILE NUMBER 001-38976

Genmab A/S

(Exact name of Registrant as specified in its charter)

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

+45 70 20 27 28

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Yes No

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENMAB A/S

BY: /s/ Anthony Pagano

Name: Anthony Pagano

Title: Executive Vice President & Chief Financial
Officer

DATE: April 12, 2021

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	Company Announcement Dated April 12, 2021: Transactions in connection with share buy-back program
99.1(a)	Appendix: Transactions April 06 – 09, 2021



Transactions in connection with share buy-back program

Company Announcement

COPENHAGEN, Denmark; April 12, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.

The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares.

The following transactions were executed under the program from April 5, 2021 to April 9, 2021:

	No. of shares	Average price (DKK)	Total value (DKK)
Accumulated through last announcement	100,000		205,583,114
April 5, 2021	0	N/A	0
April 6, 2021	1,700	2,082.08	3,539,536
April 7, 2021	1,800	2,063.35	3,714,030
April 8, 2021	1,500	2,108.68	3,163,020
April 9, 2021	1,000	2,128.01	2,128,010
Total	6,000		12,544,596
Accumulated under the program	106,000		218,127,710

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 208,977 shares as treasury shares, corresponding to 0.32% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation." Further details on the terms of the share buy-back program can be found in our company announcement no. 11 dated February 23, 2021.

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.

Genmab A/S
Kalvebod Brygge 43
21560 Copenhagen V, Denmark

Tel: +45 7020 2728
Fax: +45 7020 2729
www.genmab.com

Company Announcement no. 27
Page 1/2
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122



Transactions in connection with share buy-back program

Contact:

Marisol Peron, Senior Vice President, Global Investor Relations & Communications
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab[®]; the Y-shaped Genmab logo[®]; Genmab in combination with the Y-shaped Genmab logo[®]; HuMax[®]; DuoBody[®]; DuoBody in combination with the DuoBody logo[®]; HexaBody[®]; HexaBody in combination with the HexaBody logo[®]; DuoHexaBody[®]; HexElect[®]; and UniBody[®]. Arzerra[®] and Kesimpta[®] are trademarks of Novartis AG or its affiliates. DARZALEX[®] and DARZALEX FASPRO[®] are trademarks of Janssen Pharmaceutica NV. TEPEZZA[®] is a trademark of Horizon Therapeutics plc.

Genmab A/S
Kalvebod Brygge 43
21560 Copenhagen V, Denmark

Tel: +45 7020 2728
Fax: +45 7020 2729
www.genmab.com

Company Announcement no. 27
Page 2/2
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122





APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

Volume	Price	Venue	Time CET
20	2111	XCSE	20210409 9:00:12.371000
21	2115	XCSE	20210409 9:03:33.086000
28	2114	XCSE	20210409 9:07:54.187000
21	2109	XCSE	20210409 9:10:59.663000
17	2110	XCSE	20210409 9:16:08.193000
4	2110	XCSE	20210409 9:16:08.193000
13	2120	XCSE	20210409 9:28:09.221000
17	2120	XCSE	20210409 9:28:09.221000
10	2120	XCSE	20210409 9:30:01.722000
20	2123	XCSE	20210409 9:37:48.861000
22	2130	XCSE	20210409 9:46:17.966000
18	2129	XCSE	20210409 9:54:44.375000
1	2129	XCSE	20210409 9:54:44.375000
23	2130	XCSE	20210409 10:07:26.770000
3	2128	XCSE	20210409 10:18:32.814000
16	2128	XCSE	20210409 10:18:32.814000
10	2123	XCSE	20210409 10:29:26.129000
9	2123	XCSE	20210409 10:29:29.828000
24	2123	XCSE	20210409 10:42:35.881000
19	2121	XCSE	20210409 10:54:45.139000
23	2123	XCSE	20210409 11:11:39.474000
6	2123	XCSE	20210409 11:11:39.474000
27	2129	XCSE	20210409 11:24:31.352000
16	2131	XCSE	20210409 11:46:21.630000
23	2132	XCSE	20210409 11:48:01.405000
27	2133	XCSE	20210409 12:07:37.547000
19	2135	XCSE	20210409 12:26:43.474000
2	2139	XCSE	20210409 12:38:23.331000
21	2141	XCSE	20210409 12:40:07.877000
19	2134	XCSE	20210409 12:56:17.801000
19	2135	XCSE	20210409 13:08:12.895000
19	2133	XCSE	20210409 13:24:25.827000
23	2139	XCSE	20210409 13:49:05.900000
6	2139	XCSE	20210409 13:49:05.900000
14	2137	XCSE	20210409 14:05:43.072000
5	2137	XCSE	20210409 14:05:43.072000



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

26	2133 XCSE	20210409 14:19:23.897000
19	2135 XCSE	20210409 14:26:29.122000
16	2134 XCSE	20210409 14:33:20.651000
3	2134 XCSE	20210409 14:33:20.651000
25	2136 XCSE	20210409 14:44:29.182000
19	2134 XCSE	20210409 14:52:11.333000
19	2134 XCSE	20210409 15:06:56.058000
22	2137 XCSE	20210409 15:09:19.442000
19	2138 XCSE	20210409 15:19:04.954000
21	2137 XCSE	20210409 15:20:26.111000
21	2136 XCSE	20210409 15:26:43.220000
19	2129 XCSE	20210409 15:32:45.087000
19	2123 XCSE	20210409 15:38:24.769000
6	2125 XCSE	20210409 15:47:03.383000
8	2125 XCSE	20210409 15:47:03.404000
8	2125 XCSE	20210409 15:47:03.405000
21	2129 XCSE	20210409 15:50:58.163000
16	2121 XCSE	20210409 15:57:31.921000
3	2121 XCSE	20210409 15:57:31.922000
19	2122 XCSE	20210409 16:02:52.168000
32	2125 XCSE	20210409 16:13:32.845000
19	2127 XCSE	20210409 16:22:38.153000
13	2127 XCSE	20210409 16:29:42.197367
22	2127 XCSE	20210409 16:29:42.197367
26	2077 XCSE	20210408 9:01:20.578000
6	2073 XCSE	20210408 9:05:07.658000
26	2079 XCSE	20210408 9:06:16.285000
25	2080 XCSE	20210408 9:09:53.686000
21	2089 XCSE	20210408 9:13:06.627000
19	2098 XCSE	20210408 9:20:16.007000
1	2103 XCSE	20210408 9:23:50.176000
18	2103 XCSE	20210408 9:23:50.176000
22	2101 XCSE	20210408 9:32:18.331000
15	2110 XCSE	20210408 9:41:54.417000
6	2110 XCSE	20210408 9:41:54.417000
19	2110 XCSE	20210408 9:50:53.020000
3	2108 XCSE	20210408 10:00:00.265000



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

10	2108 XCSE	20210408 10:00:35.426000
20	2112 XCSE	20210408 10:07:33.927000
5	2113 XCSE	20210408 10:18:04.776000
7	2113 XCSE	20210408 10:18:04.776000
7	2113 XCSE	20210408 10:18:04.776000
19	2105 XCSE	20210408 10:28:23.438000
19	2103 XCSE	20210408 10:40:13.086000
19	2099 XCSE	20210408 10:49:41.523000
19	2102 XCSE	20210408 11:00:22.822000
19	2106 XCSE	20210408 11:11:54.376000
14	2107 XCSE	20210408 11:23:53.759000
6	2107 XCSE	20210408 11:23:53.759000
19	2104 XCSE	20210408 11:33:26.598000
19	2098 XCSE	20210408 11:45:15.007000
26	2102 XCSE	20210408 12:02:25.430000
5	2101 XCSE	20210408 12:02:25.430674
37	2101 XCSE	20210408 12:02:25.564735
8	2101 XCSE	20210408 12:03:04.591550
19	2101 XCSE	20210408 12:16:46.078000
10	2098 XCSE	20210408 12:31:46.082578
1	2098 XCSE	20210408 12:31:46.082578
10	2098 XCSE	20210408 12:31:46.082641
19	2098 XCSE	20210408 12:34:09.433000
5	2098 XCSE	20210408 12:34:09.433221
5	2098 XCSE	20210408 12:34:09.433245
19	2098 XCSE	20210408 12:34:09.433274
19	2101 XCSE	20210408 12:47:49.969000
1	2107 XCSE	20210408 13:06:37.150000
24	2106 XCSE	20210408 13:06:55.806000
18	2108 XCSE	20210408 13:22:30.047000
19	2113 XCSE	20210408 13:38:11.257000
19	2111 XCSE	20210408 13:43:56.948000
25	2112 XCSE	20210408 13:57:04.407000
30	2116 XCSE	20210408 14:18:13.150000
19	2116 XCSE	20210408 14:25:48.247000
20	2116 XCSE	20210408 14:25:48.247000
21	2113 XCSE	20210408 14:33:45.144000



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

21	2114 XCSE	20210408 14:43:08.737000
13	2114 XCSE	20210408 14:43:08.737000
10	2114 XCSE	20210408 14:43:08.737000
19	2113 XCSE	20210408 14:49:19.023000
10	2115 XCSE	20210408 14:58:26.079000
9	2115 XCSE	20210408 14:58:26.097000
20	2116 XCSE	20210408 15:01:45.005000
19	2114 XCSE	20210408 15:06:32.801000
17	2115 XCSE	20210408 15:14:19.022000
11	2115 XCSE	20210408 15:14:28.612000
19	2114 XCSE	20210408 15:19:24.804000
19	2114 XCSE	20210408 15:26:26.335000
2	2114 XCSE	20210408 15:26:49.302000
20	2114 XCSE	20210408 15:26:49.302000
19	2114 XCSE	20210408 15:29:21.021000
20	2111 XCSE	20210408 15:32:40.144000
15	2116 XCSE	20210408 15:38:43.444000
9	2118 XCSE	20210408 15:43:27.708000
10	2118 XCSE	20210408 15:43:31.428000
19	2118 XCSE	20210408 15:43:31.428000
19	2115 XCSE	20210408 15:48:57.423000
19	2121 XCSE	20210408 15:54:52.465000
19	2125 XCSE	20210408 15:57:04.271000
20	2123 XCSE	20210408 16:01:55.234000
19	2121 XCSE	20210408 16:06:19.618000
15	2120 XCSE	20210408 16:13:03.916000
1	2120 XCSE	20210408 16:13:04.063000
19	2120 XCSE	20210408 16:13:26.221000
15	2114 XCSE	20210408 16:21:06.024000
4	2114 XCSE	20210408 16:21:06.024000
7	2113 XCSE	20210408 16:36:23.740000
12	2113 XCSE	20210408 16:36:23.882000
19	2115 XCSE	20210408 16:38:31.642000
6	2114 XCSE	20210408 16:41:07.022183
19	2114 XCSE	20210408 16:41:07.022228
34	2114 XCSE	20210408 16:41:07.022252
30	2114 XCSE	20210408 16:41:07.022266



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

30	2114 XCSE	20210408 16:41:07.022270
25	2114 XCSE	20210408 16:41:07.039583
9	2114 XCSE	20210408 16:41:07.040399
25	2115 XCSE	20210408 16:42:41.538064
25	2115 XCSE	20210408 16:42:41.588998
4	2115 XCSE	20210408 16:42:41.588998
10	2115 XCSE	20210408 16:42:43.088239
6	2115 XCSE	20210408 16:42:47.022797
20	2086 XCSE	20210407 9:00:06.393000
19	2080 XCSE	20210407 9:02:59.654000
20	2078 XCSE	20210407 9:06:09.105000
19	2070 XCSE	20210407 9:09:08.985000
20	2060 XCSE	20210407 9:11:58.793000
20	2062 XCSE	20210407 9:17:24.780000
100	2050 XCSE	20210407 9:19:55.026369
20	2050 XCSE	20210407 9:23:37.664000
19	2053 XCSE	20210407 9:31:47.636000
20	2055 XCSE	20210407 9:40:16.073000
20	2058 XCSE	20210407 9:50:01.276000
19	2057 XCSE	20210407 9:58:35.050000
34	2056 XCSE	20210407 10:17:48.389000
19	2060 XCSE	20210407 10:28:33.356000
32	2064 XCSE	20210407 10:45:19.293000
21	2067 XCSE	20210407 10:56:09.786000
19	2068 XCSE	20210407 11:07:39.071000
19	2063 XCSE	20210407 11:19:10.686000
16	2061 XCSE	20210407 11:30:19.417000
20	2061 XCSE	20210407 11:39:19.629000
19	2066 XCSE	20210407 11:52:10.577000
13	2067 XCSE	20210407 12:02:37.297000
3	2067 XCSE	20210407 12:02:37.297000
19	2068 XCSE	20210407 12:13:02.733000
8	2073 XCSE	20210407 12:27:42.005000
7	2073 XCSE	20210407 12:28:15.352000
4	2073 XCSE	20210407 12:28:15.352000
19	2075 XCSE	20210407 12:47:53.742000
19	2073 XCSE	20210407 12:58:40.224000



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

19	2071 XCSE	20210407 13:15:13.218000
22	2068 XCSE	20210407 13:33:40.742000
19	2066 XCSE	20210407 13:44:41.164000
32	2060 XCSE	20210407 14:00:39.632285
19	2061 XCSE	20210407 14:03:28.238000
68	2060 XCSE	20210407 14:03:28.773842
19	2062 XCSE	20210407 14:22:26.294000
23	2063 XCSE	20210407 14:30:50.355000
10	2063 XCSE	20210407 14:30:50.355674
10	2063 XCSE	20210407 14:30:50.372732
80	2063 XCSE	20210407 14:30:50.372732
31	2064 XCSE	20210407 14:37:41.979000
19	2069 XCSE	20210407 14:46:04.743000
1	2068 XCSE	20210407 14:54:17.171000
18	2068 XCSE	20210407 14:54:17.359000
19	2066 XCSE	20210407 15:03:04.974000
19	2065 XCSE	20210407 15:08:50.532000
1	2066 XCSE	20210407 15:13:03.598000
19	2068 XCSE	20210407 15:16:07.850000
20	2068 XCSE	20210407 15:16:07.850000
19	2066 XCSE	20210407 15:22:09.007000
20	2067 XCSE	20210407 15:23:26.084000
19	2061 XCSE	20210407 15:27:19.662000
19	2060 XCSE	20210407 15:29:49.951000
19	2054 XCSE	20210407 15:33:08.179000
80	2050 XCSE	20210407 15:34:07.696002
20	2050 XCSE	20210407 15:34:07.696573
23	2054 XCSE	20210407 15:37:41.450000
19	2060 XCSE	20210407 15:39:07.695000
15	2064 XCSE	20210407 15:42:24.782000
5	2064 XCSE	20210407 15:42:24.782000
19	2061 XCSE	20210407 15:47:56.284000
29	2069 XCSE	20210407 15:49:40.565000
19	2069 XCSE	20210407 15:53:46.888000
19	2069 XCSE	20210407 15:53:46.888000
19	2071 XCSE	20210407 15:59:02.924000
21	2071 XCSE	20210407 15:59:02.924000



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

19	2069 XCSE	20210407 16:03:57.682000
22	2069 XCSE	20210407 16:04:59.495000
5	2068 XCSE	20210407 16:09:06.177000
11	2068 XCSE	20210407 16:09:07.123000
3	2068 XCSE	20210407 16:09:07.590000
7	2068 XCSE	20210407 16:13:55.686000
10	2068 XCSE	20210407 16:14:04.410000
7	2068 XCSE	20210407 16:14:05.686000
3	2068 XCSE	20210407 16:14:51.642000
16	2068 XCSE	20210407 16:15:44.663000
9	2068 XCSE	20210407 16:19:27.966000
10	2068 XCSE	20210407 16:19:31.391000
10	2067 XCSE	20210407 16:21:44.194000
10	2067 XCSE	20210407 16:21:44.194000
9	2069 XCSE	20210407 16:29:31.861000
8	2069 XCSE	20210407 16:29:36.712000
12	2069 XCSE	20210407 16:30:23.613000
20	2067 XCSE	20210407 16:35:37.328000
20	2066 XCSE	20210407 16:40:05.340291
30	2066 XCSE	20210407 16:40:05.340313
30	2066 XCSE	20210407 16:40:05.340316
10	2066 XCSE	20210407 16:40:05.340345
27	2066 XCSE	20210407 16:40:05.414599
20	2066 XCSE	20210407 16:40:05.414599
13	2066 XCSE	20210407 16:40:09.440598
19	2098 XCSE	20210406 9:00:10.308000
19	2096 XCSE	20210406 9:03:12.949000
20	2099 XCSE	20210406 9:06:07.896000
1	2095 XCSE	20210406 9:09:17.663000
7	2095 XCSE	20210406 9:09:17.663000
11	2095 XCSE	20210406 9:09:17.663000
20	2082 XCSE	20210406 9:12:01.552000
20	2067 XCSE	20210406 9:18:15.081000
9	2068 XCSE	20210406 9:25:00.359000
10	2068 XCSE	20210406 9:25:01.284000
19	2069 XCSE	20210406 9:33:03.179000
19	2074 XCSE	20210406 9:41:16.670000



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

20	2085 XCSE	20210406 9:50:58.558000
19	2092 XCSE	20210406 10:00:04.734000
21	2091 XCSE	20210406 10:10:31.095000
13	2091 XCSE	20210406 10:22:00.586000
7	2091 XCSE	20210406 10:22:00.586000
19	2085 XCSE	20210406 10:33:07.804000
19	2090 XCSE	20210406 10:45:04.464000
21	2089 XCSE	20210406 10:54:54.185000
21	2087 XCSE	20210406 11:05:58.151000
10	2085 XCSE	20210406 11:21:42.636000
16	2085 XCSE	20210406 11:21:42.636000
19	2085 XCSE	20210406 11:33:58.757000
19	2090 XCSE	20210406 11:45:15.042000
21	2084 XCSE	20210406 11:56:42.045000
21	2083 XCSE	20210406 12:11:57.400000
19	2084 XCSE	20210406 12:25:36.527000
20	2084 XCSE	20210406 12:41:46.429000
19	2085 XCSE	20210406 12:56:57.473000
19	2084 XCSE	20210406 13:13:16.597000
20	2086 XCSE	20210406 13:27:26.388000
19	2083 XCSE	20210406 13:44:34.456000
20	2086 XCSE	20210406 13:58:28.808000
1	2087 XCSE	20210406 14:19:00.930000
20	2086 XCSE	20210406 14:19:17.808000
19	2085 XCSE	20210406 14:26:04.603000
38	2086 XCSE	20210406 14:38:20.446000
37	2086 XCSE	20210406 14:38:20.446000
12	2087 XCSE	20210406 14:48:46.961000
14	2087 XCSE	20210406 14:48:46.961000
27	2087 XCSE	20210406 14:48:46.961000
19	2086 XCSE	20210406 14:57:49.894000
19	2086 XCSE	20210406 14:57:49.894000
17	2085 XCSE	20210406 15:01:24.509518
33	2085 XCSE	20210406 15:01:24.509551
19	2085 XCSE	20210406 15:04:11.487000
2	2085 XCSE	20210406 15:04:11.487000
17	2085 XCSE	20210406 15:04:11.487000



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

19	2085 XCSE	20210406 15:10:38.979000
19	2085 XCSE	20210406 15:10:38.979000
22	2086 XCSE	20210406 15:18:36.819000
19	2086 XCSE	20210406 15:18:36.819000
3	2085 XCSE	20210406 15:25:33.602000
4	2085 XCSE	20210406 15:26:39.218000
13	2085 XCSE	20210406 15:26:52.852000
19	2085 XCSE	20210406 15:26:52.852000
24	2085 XCSE	20210406 15:31:29.222000
24	2085 XCSE	20210406 15:31:29.222000
20	2079 XCSE	20210406 15:36:08.032000
15	2080 XCSE	20210406 15:40:10.814000
11	2080 XCSE	20210406 15:40:10.814000
19	2079 XCSE	20210406 15:41:30.274000
23	2082 XCSE	20210406 15:46:06.780000
19	2081 XCSE	20210406 15:49:03.686000
20	2080 XCSE	20210406 15:51:51.717000
10	2080 XCSE	20210406 15:52:18.586513
40	2080 XCSE	20210406 15:52:18.586544
20	2078 XCSE	20210406 15:52:59.015000
10	2075 XCSE	20210406 15:57:05.330000
9	2075 XCSE	20210406 15:57:05.330000
24	2077 XCSE	20210406 15:58:54.782000
5	2078 XCSE	20210406 16:03:58.005000
17	2078 XCSE	20210406 16:03:58.005000
19	2078 XCSE	20210406 16:04:05.512000
21	2075 XCSE	20210406 16:10:24.067000
19	2075 XCSE	20210406 16:10:24.067000
10	2075 XCSE	20210406 16:14:40.530933
2	2075 XCSE	20210406 16:15:32.792167
10	2075 XCSE	20210406 16:15:32.792167
10	2075 XCSE	20210406 16:16:21.038153
30	2075 XCSE	20210406 16:16:21.038242
10	2075 XCSE	20210406 16:16:21.071682
30	2075 XCSE	20210406 16:16:21.071732
10	2075 XCSE	20210406 16:16:30.949227
30	2075 XCSE	20210406 16:16:30.949248



APPENDIX Share buy-back programme - Specification for April 06 - 09, 2021

30	2075 XCSE	20210406 16:16:30.949251
30	2075 XCSE	20210406 16:16:30.949289
2	2075 XCSE	20210406 16:16:30.949900
6	2075 XCSE	20210406 16:16:30.949940
1	2075 XCSE	20210406 16:16:30.949942
2	2075 XCSE	20210406 16:16:30.949942
3	2075 XCSE	20210406 16:16:30.949969
30	2075 XCSE	20210406 16:16:30.949987
30	2075 XCSE	20210406 16:16:30.949989
30	2075 XCSE	20210406 16:16:30.950041
6	2075 XCSE	20210406 16:16:31.441691
1	2075 XCSE	20210406 16:16:42.110369
3	2075 XCSE	20210406 16:16:42.110624
17	2075 XCSE	20210406 16:16:42.110667
10	2075 XCSE	20210406 16:16:42.110694